Does TAFASITAMAB Cause Lymphadenopathy? 22 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Lymphadenopathy have been filed in association with TAFASITAMAB (MONJUVI). This represents 1.6% of all adverse event reports for TAFASITAMAB.
22
Reports of Lymphadenopathy with TAFASITAMAB
1.6%
of all TAFASITAMAB reports
4
Deaths
7
Hospitalizations
How Dangerous Is Lymphadenopathy From TAFASITAMAB?
Of the 22 reports, 4 (18.2%) resulted in death, 7 (31.8%) required hospitalization, and 1 (4.5%) were considered life-threatening.
Is Lymphadenopathy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAFASITAMAB. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Diffuse large b-cell lymphoma (346)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
What Other Drugs Cause Lymphadenopathy?
ADALIMUMAB (1,637)
RITUXIMAB (1,209)
METHOTREXATE (962)
PREDNISONE (958)
CYCLOPHOSPHAMIDE (941)
IBRUTINIB (929)
ETANERCEPT (802)
DUPILUMAB (760)
DOXORUBICIN (705)
VINCRISTINE (649)
Which TAFASITAMAB Alternatives Have Lower Lymphadenopathy Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR